Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | AGER | Q15109 | 2/20 | 0.38 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.38 |
| ▸ | G6PC1 | P35575 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12468905 | 1.00 | SLC18A3 (0.45) | SLC18A3SLC6A2SLC6A4AGERMTNR1A | |
| SCHEMBL14943954 | 0.95 | SLC18A3 (0.47) | SLC18A3SLC6A2SLC6A4AGERMTNR1A | |
| SCHEMBL14873965 | 0.79 | SLC18A3 (0.66) | SLC18A3SLC6A2SLC6A4AGERMTNR1A | |
| SCHEMBL15610809 | 0.79 | SLC18A3 (0.66) | SLC18A3SLC6A2SLC6A4AGERMTNR1A | |
| SCHEMBL15610808 | 0.79 | SLC18A3 (0.66) | SLC18A3SLC6A2SLC6A4AGERMTNR1A | |
| SCHEMBL12685154 | 0.79 | SLC18A3 (0.66) | SLC18A3SLC6A2SLC6A4AGERMTNR1A | |
| SCHEMBL13017781 | 0.77 | SLC6A2 (0.53) | SLC18A3SLC6A2SLC6A4AGERG6PC1 | |
| SCHEMBL26879524 | 0.76 | SLC18A3 (0.50) | SLC18A3SLC6A2SLC6A4MEN1KMT2A | |
| SCHEMBL25418952 | 0.76 | SLC18A3 (0.58) | SLC18A3SLC6A2SLC6A4AGEROPRM1 | |
| SCHEMBL18555802 | 0.76 | SLC18A3 (0.43) | SLC18A3SLC6A2SLC6A4MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9403798-B2 | Triazinone compound and T-type calcium channel inhibitor | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2016-08-02 | — | — | US | disclosed |
| US-20150065705-A1 | TRIAZINONE COMPOUND AND T-TYPE CALCIUM CHANNEL INHIBITOR | NISSAN CHEMICAL CORPORATION (JP) | 2015-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150065705-A1 | TRIAZINONE COMPOUND AND T-TYPE CALCIUM CHANNEL INHIBITOR | CACNA1E, CACNA1I, CACNA1G | SLC18A3 1294/4885SLC6A2 365/4885SLC6A4 577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.